Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial
Table 3
Summary of adverse events.
Safety population () (%)
Serious adverse events (SAEs)
Nonfatal APTC ATE events (not related to trial treatment)
1 (4.2)
Stroke
1 (4.2)
Other nonfatal SAEs
1 (4.2)
Systemic (nonocular; not related to trial treatment)
Lung neoplasm surgery
1 (4.2)
Adverse events (AEs)
Nonserious ocular AEs (not related to trial treatment)
5 (20.8)
Keratitis
2 (8.3)
Vitreous detachment
2 (8.3)
Aggravated cataract
1 (4.2)
Epiretinal membrane
1 (4.2)
Hyposphagma
1 (4.2)
Increased intraocular pressure
1 (4.2)
Nonserious systemic (nonocular) AEs (not related to trial treatment)
